Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes (NCT06851325) | Clinical Trial Compass
CompletedNot Applicable
Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes
United States6,180 participantsStarted 2023-05-01
Plain-language summary
The MIRON-PLATELET study is a retrospective, observational multi-center analysis assessing the impact of different antiplatelet therapies on hemorrhagic myocardial infarction (HMI) incidence and outcomes in STEMI patients. Key endpoints include hemorrhagic transformation, MACE, bleeding complications, and 30-day mortality. Findings will offer insights into the safety and clinical implications of antiplatelet therapy in high-risk patients.
Who can participate
Age range
18 Years – 79 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥18-79 years at the time of STEMI diagnosis
. Diagnosed with ST-segment elevation myocardial infarction (STEMI) based on standard clinical criteria
. Received antiplatelet therapy as part of STEMI management
. Evidence of hemorrhagic MI confirmed by Cardiac Magnetic Resonance Imaging OR Post-PCI biomarker diagnostics
. Availability of comprehensive medical records documenting STEMI presentation, treatment details, and clinical outcomes
. Minimum of 30-day follow-up data, with extended follow-up available for up to 10 years
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study looked at how different antiplatelet drugs affect bleeding inside the heart muscle after a STEMI — called hemorrhagic myocardial infarction — so can you tell me which antiplatelet therapy I'm receiving and whether the findings from this study might be relevant to my treatment plan?
2Since this trial has already been completed, has any data or results been published yet, and if so, what did they find about which antiplatelet therapies were linked to higher or lower rates of intramyocardial hemorrhage?
3Intramyocardial hemorrhage sounds serious — can you explain what it means for my recovery if it happens, and how the results of this study might inform decisions about my antiplatelet therapy going forward?
4Are there different antiplatelet therapy options available to me right now, and based on what this study found, is there reason to prefer one over another in my specific situation?
5Since this was an observational or non-interventional study rather than a randomized trial, how much weight should I give its findings when thinking about my own treatment compared to evidence from controlled clinical trials?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of Hemorrhagic Myocardial Infarction (HMI) in STEMI Patients Receiving Different Antiplatelet Therapies